Category: News

ZURICH, Switzerland, December 2024 – Venture Valuation/Biotechgate (the “Company”) a leader in life science valuation and data solutions, is pleased to announce its participation in JPM Week 2025, taking place in San Francisco this January. The week, centered around the J.P. Morgan Healthcare Conference, is one of the most significant gatherings in the life sciences calendar.

During the week, the Company will attend the following events:

• Sachs 8^th Annual Neuroscience Innovation Forum – January 12, 2025
• Biotech Showcase – January 13-15, 2025
• RESI (Redefining Early Stage Investments) JPM 2025 – January 14, 2025

Highlighting the Company’s presence at JPM Week, CEO Dr. Patrik Frei will deliver a presentation at the RESI event, focusing on life science company valuation strategies and best practices.

“JPM Week is the most important event in the life sciences calendar, and we are excited to participate as well as connect and re-connect with fellow life science professionals,” said Dr. Frei. “Our presence at these events underscores our commitment to supporting the life sciences ecosystem with accurate, data-driven insights and valuations that drive informed decision-making.”

The Company welcomes the opportunity to connect with attendees during these events and provide insights into solutions for the ever-evolving biotech landscape. Registered attendees can schedule a one-on-one meeting with the Company’s delegates using the conference portals. Alternatively, they can get in touch at contact@venturevaluation.com.

About Venture Valuation:

Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.

The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents.  Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 60,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 35,000 licensing deals and a clinical trials database containing over 900,000 records from registries around the world.

ZURICH, Switzerland, November 2024 – Biotechgate, a leading provider of life sciences information and partnering solutions, is pleased to announce its strategic collaboration with BioFlorida. This partnership aims to strengthen the data integration in Biotechgate while enhancing the visibility and insights of the life sciences industry in Florida.

As a key initiative of this new alliance, BioFlorida is supporting Biotechgate’s USA Life Sciences Databasme (www.usalifesciences.com) alongside other partners. The database serves as a comprehensive platform where BioFlorida’s members, spanning the entire life sciences spectrum, will be publicly visible, further expanding their reach and connectivity within the industry.

Biotechgate, as part of its commitment to supporting BioFlorida, will contribute additional data on the life sciences industry in Florida. This will enrich both the global Biotechgate platform and the USA Life Sciences database with valuable resources and industry trends. Additionally, Biotechgate will provide BioFlorida with an annual Trend Analysis Report, offering in-depth analysis and statistics on the state’s life sciences sector to aid in strategic decision-making.

“We are delighted to establish this collaborative partnership with BioFlorida,” stated Dr. Patrik Frei, CEO and Founder of Venture Valuation/Biotechgate. “By combining our expertise and resources, we aim to facilitate networking opportunities and promote the overall advancement of Florida’s life science sector. The synergy between Biotechgate and BioFlorida will pave the way for enhanced data integration, global industry visibility, and valuable insights that aim to benefit all stakeholders.”

BioFlorida President and CEO, Mark Glickman, said, “We are thrilled to announce our strategic partnership with Biotechgate, a leading provider of VC databases and life sciences intelligence. This collaboration will revolutionize our members’ access to critical data, fueling growth and innovation in Florida’s life sciences ecosystem.

Through this partnership, we will:

• Enhance global connectivity and collaboration
• Provide exclusive access to Biotechgate’s extensive VC databases
• Deliver customized analytics and insights to drive business decisions
• Foster unparalleled growth and opportunities for our membership

Our joint vision extends beyond data integration. We aim to create a comprehensive infrastructure that empowers our members to leverage critical data, streamline processes, and achieve strategic goals.

The BioFlorida and Biotechgate teams are committed to listening to your needs and delivering tailored solutions.”

To browse comprehensive profiles of BioFlorida’s members, visit the USA Life Sciences Database at: www.usalifesciences.com.

---

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 60,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 35,000 licensing deals and a clinical trials database containing over 900,000 records from registries around the world.

About BioFlorida:

From Concept to Consumer, BioFlorida is the premier source for supporting Florida’s life sciences industry, representing a diverse range of sectors including BioPharma, MedTech, Digital Health, Health Systems, and supporting organizations.

They provide comprehensive resources and advocacy while fostering a thriving community that leads in innovation, delivering groundbreaking solutions that benefit patients.

BioFlorida’s value-driven membership supports the life sciences ecosystem through increased Visibility, Industry Insights, Education & Information, Networking & Events, Cost Savings, Policy & Advocacy, and Capital & Growth Opportunities.

By connecting Florida’s life sciences industry with local, national, and global opportunities, BioFlorida plays a vital role in driving innovation and growth, positioning the state as a leader in the field.

Virtual conference Dec 2-6, 2024, prepares life science dealmakers ahead of the 2025 J.P. Morgan Health Conference

SAN FRANCISCO and ZURICH, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) — Big4Bio and Biotechgate are proud to announce the launch of a new annual conference for the life science industry, Pre-JPM Partnering Week, presented virtually Dec 2-6, 2024. The event has been created to not only be the final partnering event of the year, but also an integral part of preparation for the week of the J.P. Morgan Healthcare Conference (“JPM Week”) in January 2025.

As the closing event of Biotechgate’s quarterly Digital Partnering conference series, Pre-JPM Partnering Week will be:

• A complete digital partnering conference, including one week of virtual one-on-one meetings, “Pop-up Coffee” sessions, as well as workshops and presentations to support the business development and licensing activities of pharma, biotech, medtech, and digital health companies;
• A consummate preparation event for JPM Week 2025, comprised of JPM-prep panels with industry experts, presentations about JPM resources, opportunities to connect with JPM attendees to establish meeting possibilities, and more;
• A thorough review of the “year that was” as well as predictions/thoughts of what’s to come for 2025 via the insights of Big4Bio-area executives, industry media professionals and analysts, and other leaders in the life sciences.

“We are very thrilled to work with Big4Bio and integrate our joint event with our quarterly Biotechgate Digital Partnering event. We can leverage the network, reach and previous pre-JPM events of Big4Bio as well as built on the past success of the 17 Biotechgate Digital Partnering events,” comments Patrik Frei, CEO and founder of Venture Valuation/Biotechgate.

The event will provide dealmakers and executives with a unique business networking opportunity to cap off 2024, including presentations and panels from leading JPM event organizers and other notable industry organizations such as Demy-Colton and The Bullpen.

“Big4Bio has been providing coverage and guides for JPM Week/BioWeekSF for almost a decade, and we’re excited about this new way to further connect JPM stakeholders and attendees,” said Tilton Little, publisher of Big4Bio. “With Biotechgate’s Digital Partnering Series groundbreaking in connecting the global community virtually, we felt this was the perfect joining of resources and audiences.”

For more information about registration or participation, go to digitalpartnering.com.

About Big4Bio

Big4Bio is the premier aggregator of news and developments in the life sciences sector. Its free, daily email newsletters give readers easy-to-scan headlines of bioscience content gleaned from thousands of industry sources, focusing on the most significant life sciences markets in the world: Boston, San Francisco Bay Area, San Diego, Philadelphia, DC/VA/MD region (Capital Region), New York City, Los Angeles, and Seattle. For more information, go to big4bio.com.

About Biotechgate / Venture Valuation

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 60,000 life science company profiles. Thanks to its unique data-sourcing process makes it an invaluable resource for life sciences start-ups, pharma companies, investors, and other BD and industry professionals. Biotechgate is part of Venture Valuation Inc, a company specialized in asset and company valuation for fundraising, investments and licensing. The company also created the HelloPartnering software and runs Biotechgate Digital Partnering events. www.biotechgate.com / www.venturevaluation.com

ZURICH, Switzerland, May 2024 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation in the highly anticipated 2024 BIO International Convention taking place June 3-6, 2024, at the San Diego Convention Center, in San Diego, California, USA.

The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering and brings together thousands of global biotechnology and biopharmaceutical leaders. The four-day event includes networking, programming and partnering opportunities.

The Company welcomes attendees to visit booth number 2111 in the Swiss Biotech Pavilion to learn more about its independent valuation services, life sciences database, and quarterly partnering events. Its team of experts will be available for discussions and to provide insights into solutions for the ever-evolving biotech landscape. Registered attendees can also schedule a one-on-one meetings with the Company’s delegates using the conference portal.

The Company Chief Executive Officer, Dr. Patrik Frei, and Senior Consultant, Dr. Gergely Iványi, will be presenting a course on the topic of “Product and Company Valuation” on June 2, 2024, also at the San Diego Convention Center. The course will teach how to produce a valuation to be used in investment rounds, mergers and acquisitions, licensing deals, or strategic decisions in the life sciences industry.

About Venture Valuation:

Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.

The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology, medical technology, nanotechnology, renewable energies and information technology / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents.  Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 60,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 35,000 licensing deals and a clinical trials database containing over 900,000 records from registries around the world.

ZURICH, Switzerland, December 2023 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation at Biotech Showcase and Redefining Early Stage Investments (RESI) alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.

During the aforementioned events, the Company team will conduct one-to-one meetings discussing their independent valuation services, life sciences database, and quarterly partnering events. Their team of experts will be available for discussions and to provide insights into solutions for the ever-evolving biotech landscape. Registered attendees can schedule a one-on-one meeting with the Company’s delegates using the conference portals. Alternatively, get in touch at contact@venturevaluation.com to arrange a meeting.

About Venture Valuation:

Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.

The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents.  Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.

About Biotechgate: Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 70,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

Zurich, Switzerland, December 2023 – Venture Valuation announces that it has appointed Bill Colihan and David Tucker as BD Directors to strengthen its expansion in North America. The new appointments’ primary focus will be on Venture Valuation’s Biotechgate database, a unique business development and licensing platform for the life sciences industry.

Both BD directors are located in the USA and will take care of the North American market. Bill Colihan has extensive experience in the business development of innovative information services and previously served as President of Knowledge Express. He holds a BA from the University of Delaware and an MBA from Villanova University.

David Tucker combines an investment banking background with 15 years of experience in life science business development, leadership and consulting. He graduated from Colorado State University with an MBA and is currently pursuing a Master’s degree in Biotechnology from Johns Hopkins University.

Together with the existing sales teams in Asia and Europe, Biotechgate now covers all time zones and thus enables an even better service for all customers and partners.  “I’m thrilled to welcome Bill and David to the team as we continue to grow our presence and better serve our North America-based clients. Both possess strong skillsets and a wealth of previous experience in BD intelligence that will be a valuable asset to our company going forward,” said Patrik Frei, chief executive officer of Venture Valuation.

If you wish to get in touch with the North American sales team, you can reach out through the Biotechgate website or by connecting with them on LinkedIn:

• Bill Colihan, BD Director US-East
• David Tucker, BD Director US-West

About Venture Valuation:

Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.

The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents.  Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 70,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

---

Zurich, Switzerland and Cambridge, UK, September 2023 – Biotechgate, a leading global life sciences business development and licensing database and One Nucleus, a Cambridge, UK-based life sciences and healthcare membership organisation, are thrilled to announce a collaboration to boost life sciences connectivity and innovation. The purpose of this collaboration is to provide a reliable hub of information for professionals, organizations, and individuals across the industry by enhancing connections and promoting innovation.

A highlight of this partnership is the provision of a comprehensive member directory for One Nucleus, powered by Biotechgate. This searchable directory will offer valuable insights into company profiles, sector statistics, and up-to-date information to guide strategic decisions. One Nucleus member profiles featured on Biotechgate will be publicly accessible, expanding their reach within the industry.

The new alliance also entails the preparation of an annual financing report for the UK and Cambridge cluster using Biotechgate data. This will shed light on trends in the UK life science landscape and serve as a valuable resource for industry professionals.  

“At Biotechgate, we recognize the power of data to drive progress and innovation in the life sciences sector,” said Dr Patrik Frei, CEO of Venture Valuation, the owner of Biotechgate. “Teaming up with One Nucleus is a logical step in our journey, as it aligns perfectly with our commitment to fostering connectivity and facilitating growth opportunities for all stakeholders in the industry.”

“One Nucleus has a strong commitment to supporting innovation within the Life Sciences sector. Through this collaboration with Biotechgate, we are introducing a powerful tool to the One Nucleus website that will enable our members to be searchable across key criteria. This is important for those searching our database with the aim of identifying potential partners, investors and clients. This tool will also provide increased visibility of One Nucleus members to those searching the global life science industry not just our members, further enhancing the value of One Nucleus membership. Finally, we are delighted that our members will now receive exclusive VIP codes for future Biotechgate Digital Partnering events, reinforcing our commitment to bringing the best people together” said Tony Jones, CEO, One Nucleus.

Explore the One Nucleus member directory and visit the UK Biotech Database as the information hub for life sciences companies in the UK.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

About One Nucleus:

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organization headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity.

Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximize their performance. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.

Media Release

Zurich, Switzerland and Washington, D.C., USA, August 2023 – Biotechgate, a global business development and licensing database for the life sciences industry, is proud to announce its strategic partnership with the Advanced Medical Technology Association (AdvaMed). This collaboration aims to strengthen the data integration in Biotechgate, while enhancing the visibility and insight into the thriving medtech industry.

As a key initiative of this new alliance, AdvaMed is supporting Biotechgate’s USA Life Sciences Database (www.usalifesciences.com) along with other partners. The database serves as a comprehensive platform where AdvaMed’s more than 400 members, ranging from large medical technology companies to small medical device innovators, will be publicly visible. This will further expand their reach and connectivity within the industry.

The life sciences database Biotechgate, as part of its commitment to support AdvaMed, will contribute further data on the medtech industry. The data will enrich the global platform as well as USA Life Sciences database with valuable resources and industry trends. As a service to AdvaMed, Biotechgate will also provide an annual Trend Analysis Report, offering in-depth analysis and statistics on the medtech industry to aid in strategic decision-making.

“We are thrilled to establish this collaborative partnership with AdvaMed,” stated Dr. Patrik Frei, CEO and Founder of Venture Valuation/Biotechgate. “By combining our expertise and resources, we aim to facilitate networking opportunities and promote the overall advancement of the medtech sector. The synergy between Biotechgate and AdvaMed will pave the way for enhanced data integration, global industry visibility, and valuable insights that aim to benefit all stakeholders. We are also looking forward to promoting AdvaMed’s annual conference, The MedTech Conference, on October 9-11, 2023 in Anaheim.”

“We are excited to partner with Venture Valuation/Biotechgate to support the USA Life Science Database. The medtech industry is at the forefront of life-saving and life-changing health care innovation, with our small companies leading the way in developing the next generation of medical technology. Ensuring these early-stage startups, and even more established medtech leaders, have access to resources and investment opportunities will allow us to better serve our industry as we work to get these products into the hands of patients who need them,” said Scott Whitaker, President and Chief Executive Officer of AdvaMed.

To browse comprehensive profiles of AdvaMed’s members, visit the USA Life Sciences Database at: https://www.usalifesciences.com/.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 68,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for Medtech, pharma, start-ups, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

About AdvaMed:

AdvaMed is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. With a mission to improve patient access to safe, effective and innovative medical technologies, AdvaMed plays a pivotal role in advocating for policies that promote the highest ethical standards, appropriate reimbursement, and access to international markets.
The association supports its members through networking, education, and advocacy, driving collaboration and innovation in the healthcare industry.

ZURICH, Switzerland, May 2023 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation in the highly anticipated 2023 BIO International Convention taking place June 5-8, 2023, at the Boston Convention & Exhibition Center, in Boston, Massachusetts, USA.

The Company welcomes attendees to visit their booth at booth number 1743 in the Swiss Pavilion to learn more about their independent valuation services, life sciences database, and quarterly partnering events. Their team of experts will be available for discussions and to provide insights into solutions for the ever-evolving biotech landscape. Registered attendees can also schedule a one-on-one meeting with the Company’s delegates using the conference portal.

The Company Chief Executive Officer, Dr. Patrik Frei, will be presenting a course on the topic of “Product and Company Valuation” on June 4, 2023 also at the Boston Convention & Exhibition.  Center. The course will teach how to produce a valuation to be used in investment rounds, mergers and acquisitions, licensing deals, or strategic decisions in the life sciences industry.

Alongside the BIO International Convention, the Company will also attend in person at Redefining Early Stage Investments (RESI) on June 5, 2023, located at The Westin Copley Place, Boston. RESI is an ongoing conference series connecting start-ups and early-stage investors and strategic channel partners.

About Venture Valuation:

Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.

The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents.  Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 65,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 25,000 licensing deals and a clinical trials database containing over 750,000 records from registries around the world.

Media Release

Venture Valuation/Biotechgate Partners with ALLIS-NA: Launch of Member Directory

Zurich, Switzerland and Paris, France, March 2023 – Venture Valuation/Biotechgate is proud to announce its partnership with the French regional health cluster Alliance Innovation Santé Nouvelle-Aquitaine (ALLIS-NA). The two organizations are collaborating to accelerate both the data integration in Biotechgate and economic development of the life science industry in the Nouvelle-Aquitaine region of France.

As part of this new cooperation, Venture Valuation created and launched a comprehensive membership directory for ALLIS-NA. The directory is freely accessible on the ALLIS-NA website and features over 140 members across ten different life science sectors, including Biotechnology, Pharma, Medical Technology, Digital Health, and more. The directory is designed to help companies easily search and connect with potential partners and collaborators.

In addition to the member directory, Venture Valuation will publish its annual report on the French life sciences industry later this year on the Biotechgate website, with significant cooperation and input from ALLIS-NA. This report promises to be a valuable resource for industry professionals, investors, and start-ups.

“We are excited to join forces with ALLIS-NA as dynamic and rapidly-growing health cluster. This partnership is another big step for us and underscores our commitment to expanding our global network of key industry associations in the life science sector,” – said Dr. Patrik Frei, CEO and Founder of Venture Valuation/Biotechgate. “The directory will boost the visibility of ALLIS-NA’s members and promote the strength of the life science network in Nouvelle-Aquitaine.”

“We are pleased to engage this collaboration with Biotech gate which will both promote the visibility of our members through the enhancement of their activities and enable us, as a hub for players in the health sector, to create economic and scientific bonds with our international counterparts for the benefit of our members in the Nouvelle-Aquitaine region (France).” – said Laurence Lachamp, general manager of ALLIS-NA.

The member directory is available at: https://allis-na.fr/biotechgate-en

About Venture Valuation:

Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.

The focus lies on technology companies in fast growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents.  Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 65,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 25,000 licensing deals and a clinical trials database containing over 750,000 records from registries around the world.

About ALLIS-NA:

The Alliance Innovation Santé Nouvelle-Aquitaine (ALLIS-NA) is the healthcare hub serving all actors in the health sector in the New Aquitaine region.  The primary objective of ALLIS-NA is to take part in the consolidation and economic growth of the sector throughout the region, by promoting innovation in the health sector and strengthening the competitiveness of regional companies and the attractiveness and development of the regional health ecosystem.

Today, ALLIS-NA brings together 140 members across the entire health value chain and the region, with 5 own facilities or partnerships.